Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system

C Chufeng Ding L Lin Ma Y Yankun Liang Z Zhenpo Zhang Q Qimin Wu J Jun Lyu L Ling Su

Article Details

Volume / Issue Vol. 15, Issue 1
Published April 29, 2025
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (7)

C

Chufeng Ding

L

Lin Ma

Y

Yankun Liang

Z

Zhenpo Zhang

Q

Qimin Wu

J

Jun Lyu

L

Ling Su